We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Tripos and Cara Announce Medicinal Chemistry Partnership

Tripos and Cara Announce Medicinal Chemistry Partnership

Tripos and Cara Announce Medicinal Chemistry Partnership

Tripos and Cara Announce Medicinal Chemistry Partnership

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Tripos and Cara Announce Medicinal Chemistry Partnership"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Tripos, Inc. has announced that Tripos Discovery Research Ltd. has formed research collaboration with Cara Therapeutics. Cara is focused on developing therapeutics to treat medical conditions associated with pain and inflammation.

A team of computational and medicinal chemists at TDR will work in partnership with Cara's project team to support its drug discovery programs.

By combining Tripos' proprietary informatics tools with its expertise in medicinal chemistry, TDR's chemists will focus on the development of novel molecules for Cara's specific needs.

Based on Tripos' contribution, these molecules have the potential to progress into full clinical development more quickly than current industry norms.

"I am confident in Tripos' capabilities to accelerate discovery programs," said Dr. Derek Chalmers, CEO and president of Cara Therapeutics. "Tripos' domain expertise in this therapeutic area complements our own, and we look forward to a fruitful partnership."

"We are delighted that Cara has selected Tripos Discovery Research to support its efforts to discover new medicines in the area of neuropathic pain," said Dr. Mark Allen, senior vice president and managing director of TDR.

"The therapeutic options currently available to treat these debilitating conditions are very limited. This relationship, which leverages a component of our G-protein-coupled receptor LeadDiscovery™ library, underscores the high value attributed to our expertise and therapeutic medicinal chemistry capabilities."